At TransCode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted on several key proposals. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares. Notably, shareholders rejected the proposed reverse stock split that would have allowed a ratio between 1-for-2 and 1-for-40, with 1,277,915 votes against versus 1,018,164 in favor.Shareholders approved the election of four directors - Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet - each for one-year terms. Additionally, stockholders approved an amendment to the 2021 Stock Option and Incentive Plan to increase available shares by 3 million, and ratified WithumSmith+Brown as the company's independent auditor for FY2024.

At TransCode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted on several key proposals. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares. Notably, shareholders rejected the proposed reverse stock split that would have allowed a ratio between 1-for-2 and 1-for-40, with 1,277,915 votes against versus 1,018,164 in favor.Shareholders approved the election of four directors - Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet - each for one-year terms. Additionally, stockholders approved an amendment to the 2021 Stock Option and Incentive Plan to increase available shares by 3 million, and ratified WithumSmith+Brown as the company's independent auditor for FY2024.